Sincrolab S.L.

Sincrolab S.L. is a Spanish digital-health company based in Málaga that develops and commercialises a personalised digital treatment for attention difficulties, including ADHD (attention-deficit/hyperactivity disorder). Rather than a simple consumer app, the company positions its offering as a structured therapeutic programme: an initial online assessment with a specialist, a cognitive profile built from a pre-treatment test, daily home-based activities, and continuous professional follow-up. The company states that families typically see changes over a six-month period, with goals spanning organisation, self-regulation, reduced impulsivity and improved family wellbeing. The core product is delivered through companion applications for the child and the supervising adult, with the clinical service branded Sincroclinic. Sincroclinic is sold as a monthly subscription (listed at €99.00 EUR per month on the company's own product page) and includes booking an appointment with a specialist; the initial session carries a professional-management fee. The treatment is described as the first application created and approved by specialists in its category, and the company emphasises that it is validated by professionals and grounded in neuropsychological research. Sincrolab places heavy emphasis on clinical and regulatory credibility. Its website states that it is certified under ISO 13485:2016 (by Scarlet) for medical-device quality management, certified under ISO/IEC 27001:2022 (by Insight Assurance) for information security, compliant with the EU Medical Device Regulation through CE marking, and that patient data is processed securely in line with GDPR. These claims are central to its differentiation from general-purpose attention-training apps. The company describes its origin as the work of a clinical team specialised in neuropsychology who repeatedly saw families seeking solutions that did not fit their daily lives, and who therefore set out to build an accessible, personalised, evidence-based alternative that could be applied at home with professional supervision. Its stated mission is to help families understand what is happening and to improve children's attention from home through a clear, accessible and scientifically contrasted solution. Sincrolab operates primarily in the Spanish market, with Spanish-language marketing and online assessment and subscription flows. It is a private company; no parent company, ownership group or stock listing is indicated in the available evidence. Its taxonomy placement is as a general commercial company, though functionally it sits at the intersection of digital therapeutics, child neuropsychology and medical software.

Sincrolab S.L. is a Spanish company registered in Málaga, Spain, operating in the digital health and neuropsychology space. Public evidence about the company is concentrated in its own website and a Wikidata entry identifying it as a company in Málaga; no founding date, founder names or funding history are provided in the available sources, so those details are not asserted here. The company's own account of its origins is clinical rather than commercial: it states that Sincrolab arose from the commitment of a clinical team specialised in neuropsychology who, year after year, saw similar cases in consultation — families looking for solutions that did not fit into their daily lives. That experience led the team to create an alternative: an accessible, personalised, evidence-based treatment that could be applied from home with professional follow-up. This origin story frames the company's identity as a clinical service wrapped in software rather than a pure technology startup. Sincrolab's product architecture reflects that clinical framing. A prospective family begins with an online assessment, including a pre-treatment test used to analyse each patient's situation in the same way neuropsychologists would, and an initial online appointment that allows each case to be evaluated individually. The initial session carries a professional-management fee to guarantee thorough attention and specialist scheduling. From there, a cognitive profile is created for the patient, access credentials are issued for the applications, and the treatment begins at home. The programme is designed around daily activities, with the company stating that results are expected over six months and that each case is supervised by professionals who assess progress and adjust the treatment. The commercial vehicle for the clinical service is Sincroclinic, sold through the company's website as a monthly subscription listed at €99.00 EUR, renewable automatically and cancellable at any time. The purchase flow collects tutor and minor details, appointment preferences and application access credentials, and requires acceptance of the privacy policy and the Sincroclinic licence and use agreement. This indicates a direct-to-consumer model in the Spanish market, with the specialist consultation embedded in the subscription journey. A defining feature of Sincrolab's history and positioning is its investment in regulatory and quality credentials. The company states that it is certified under ISO 13485:2016 by Scarlet, certified under ISO/IEC 27001:2022 by Insight Assurance, compliant with the EU Medical Devices Regulation via CE marking, and that patient data is processed securely under GDPR. It also describes its treatment as the only application created and approved by specialists, and as developed from neuropsychological research and scientifically validated. These claims position Sincrolab within the regulated medical-device and digital-therapeutics landscape rather than the general wellness-app market. Beyond these elements, the available evidence does not document specific dated milestones such as incorporation, product launches, funding rounds, partnerships, executive appointments or expansions. The company appears to operate primarily in Spain with Spanish-language materials, and no parent company, ownership group or stock listing is indicated. Its stated mission remains to help families understand what is happening and to improve children's attention from home through a clear, accessible and scientifically contrasted solution.

Clinician-supervised, evidence-based and CE-marked digital therapeutic for childhood attention difficulties, positioned as more than an app and supported by ISO 13485, ISO 27001 and GDPR compliance claims.

• Sincroclinic

  Clinical digital treatment service for attention difficulties/ADHD, sold as a monthly subscription at €99.00 EUR, including specialist appointment booking, cognitive profiling and access to companion apps.

• Sincrolab companion apps

  Applications for children and supervising adults used to deliver daily home-based attention training activities within the supervised programme.

1. 1Terapia digital TDAH | Sincrolabsincrolab.es
2. 2Sobre Sincrolabsincrolab.es
3. 3Sincroclinicsincrolab.es
4. 4Sincrolab S.L. (Spain) — Wikidatawikidata.org